Skip to main content

IL-23

Biomarkers Predictive of a Deucravacitinib Response in Psoriatic Arthritis

A phase II trial demonstrating the clinical efficacy of deucravacitinib, a TYK2 inhibitor, in psoriatic arthritis (PsA) suggests specific biologic effects identified by biomarkers may predict clinical responses.

Read Article

Canary in a Coal Mine (4.19.2024)

Dr. Jack Cush reviews regulatory reports, news and novel journal articles - this week focusing on Sjogren's, ILD, Gout and Uveitis.

Read Article
#RNL2024 @RheumNow @_AprilArmstrong Choosing a biologic in Psoriasis TNF - great in PsA, pregnancy. Avoid in demyelinating, hep B IL-17 - robust skin, PsA (axial too). Avoid in IBD IL-23 - robust skin, PsA evidence, fewer injections https://t.co/42kUaIZxKs

Dr. John Cush @RheumNow( View Tweet )

Window of Opportunity in Psoriatic Arthritis

A Dutch Early Psoriatic Arthritis cohort study shows that psoriatic arthritis (PsA) patients treated early (referred and diagnosed  within in less than 12 weeks) had the best clinical outcomes. 

Read Article

2023 EULAR Psoriatic Arthritis Recommendations

EULAR has updated its treatment recommendations from the prior 2019 guidelines, since which there have been several newly developed agents. The updated guidance includes 7 overarching principles and 11 recommendations regarding treatment strategy and pharmacological therapies.

Read Article

Expert Panel Guidance on Managing Psoriatic Arthritis and Comorbidities

An expert panel has published their consensus guidelines for the management of psoriatic arthritis (PsA) and it's comorbidities in the journal Rheumatology. 

Read Article

Immunosuppression Increasing (2.23.2024)

Dr. Jack Cush reviews the news and journal reports from the past 2 weeks on RheumNow.com; but begins with a discussion of what constitutes "immunosuppression" and how it applies to our patients.





  1. 2021 NHIS Survey data suggests the prevalence of immunosuppression in the USA

Read Article
Oral IL-23 Inhibitor Effective in Psoriasis The NEJM has published the results of the FRONTIER 1 trial demonstrating the efficacy of JNJ-77242113, an oral interleukin-23 (IL-23) receptor antagonist peptide, in patients with psoriasis (PSO). https://t.co/NRK8LnM5zp https://t.co/FnWEze976O
Dr. John Cush @RheumNow( View Tweet )
"It's hard not to be jealous of the dermatologists." @JointMD discussing the results of JNJ 77242113, po IL-23R, the Frontier 1 trial. #RWCS24 @RWCSmtg @RheumNow https://t.co/1zQ6bu5TM2
Dr. Rachel Tate @uptoTate( View Tweet )
Combo IL-23 and TNFi synergistic benefit in UC in the proof-of-concept VEGA trial. More data to come! #RWCS24 @RWCSmtg @RheumNow https://t.co/FgLTR2PBYJ
Dr. Rachel Tate @uptoTate( View Tweet )

Pre-Treatment Testing with Biologics Falls Short

US commercial insurance claim analysis of laboratory screening and monitoring practices in chronic inflammatory skin disease (CISD) patients shows that < 60% received the recommended pretreatment testing when starting systemic immunomodulatory treatment.

Read Article

2023 Rheumatology Year in Review

Dr. Jack Cush reviews highlights, advances and hot topics in rheumatology from 2023 and the RheumNow website.  



2023 was a year of growth and new horizons while returning to operational and practice standards (in care and education) established before the pandemic.  

Read Article

Enthesitis, Synovitis, and Tenosynovitis in Psoriatic Arthritis

An ultrasound study suggests that enthesitis is associated with both synovitis and tenosynovitis in patients with Psoriatic arthritis (PsA).

Read Article

Best of 2023: Does Biologic Treatment in Psoriasis Reduce the Risk of Psoriatic Arthritis?

Retrospective claims analysis shows that psoriasis patients treated with either an IL-12/23 inhibitor or an IL-23 inhibitor had a lower risk of developing incident psoriatic arthritis, compared to TNF inhibitors or IL-17 inhibitors.

Read Article

ICYMI: Bimekizumab is Coming…in Third Place

Of the many exciting advancements for patients with psoriatic arthritis at ACR Convergence, one upcoming therapy stood out: the dual IL-17A/F inhibitor bimekizumab. Nearly two dozen bimekizumab abstracts will be featured at this year’s meeting and it recently received authorization in Europe and

Read Article
UK Dermatology Registry of 13 699 Psoriasis pts on biologics (25K biologic exposures) found 1% risk of paradoxical eczema. Biologics included inhibitors of TNF, IL-17, IL12/23, IL-23. Lowest risk w/ IL-23i (0.56/100kPY), and higher w/ IL-17i (1.22) https://t.co/fOX6VGJQLk https://t.co/u1p1sidCte
Dr. John Cush @RheumNow( View Tweet )
#ACR23 Late-Breaking Abstr#L14 Which team are you on? IL5-i or IL5-receptor-i #EGPA. Phase 3 H2H RCT showed similar efficacy btw Mepolizumab and Benralizumab, with more pts fully tapering off GC at WK52 favouring BENRA. Rapid reduction in Eosinophils too @RheumNow #ACRBest https://t.co/cXhSS80mA2
Md Yuzaiful Md Yusof ( View Tweet )
Systemic anti-inflammatory treatments for PsO and PsA including methotrexate and biologics provided cardioprotective effects Potential cardiovascular benefits of IL-17i and IL-12/23i compared to TNFi @RheumNow #ACR23 Abs#0498 https://t.co/Np7PSNvFd6
Robert B Chao, MD ( View Tweet )

Bimekizumab is Coming… in Third Place

Of the many exciting advancements for patients with psoriatic arthritis at ACR Convergence, one upcoming therapy stood out: the dual IL-17A/F inhibitor bimekizumab. Nearly two dozen bimekizumab abstracts will be featured at this year’s meeting and it recently received authorization in Europe and

Read Article

Pizza and Rheumatoid Arthritis (8.11.2023)

Dr. Jack Cush reviews the news and journal reports from the wonderful wide world of Rheumatology. This week:





  1. Swedish study of 325 #AAV pts saw CVA in 35 pts (8%); CVA incidence=11.3/1000 PYs - this was higher than gen population [SIR 1.85). AAV CVA risk factors included

Read Article
IL-23 Inhibitor Performance in Psoriatic Disease A single center real-world observational study shows three commercially available IL-23 inhibitors have high and similar drug survival and effectiveness in difficult-to-treat psoriasis and PsA. https://t.co/J3HIDBguj1 https://t.co/uqYf0Bdh0n
Dr. John Cush @RheumNow( View Tweet )

IL-23 Inhibitor Performance in Psoriatic Disease

IL-23 inhibitors are approved for the treatment of psoriasis and psoriatic arthritis; a single center real-world observational study shows three commercially available IL-23 inhibitors have high and similar drug survival and effectiveness in difficult-to-treat psoriasis and PsA.

Read Article
Double blind RCT of 101 active AS patients with BASDAI ≥4 showed the IL-23 inhibitor, tildrakizumab was not superior to placebo after 24 weeks (ASAS20: 74% on tildrakizumab 200 mg vs 80% on PBO). Study was terminated after wk 24 interim analysis https://t.co/zZxiAk6A5o https://t.co/P1tNX8BN6C
Dr. John Cush @RheumNow( View Tweet )

Prevalence of Psoriatic Arthritis, Spondyloarthritis and Rheumatoid Arthritis in Norway

Recent reports have suggested a rising and unrecognized number of patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) compared to rheumatoid arthritis (RA). This has implications on diagnosis and population care.  A recent analysis of Norway registry data answers

Read Article

Disappointing Secondary Use of Newer Therapies in Psoriatic Arthritis

Analysis of patient data from five Nordic registries shows that the uptake of newer biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in psoriatic arthritis (PsA) was mainly in biologic-experienced patients. The use of newer b/tsDMARD was hampered by limited

Read Article